Zoetis Inc.: directors' dealings · United States · SEC (Form 4)

About Zoetis Inc.

Zoetis Inc. (ticker: ZTS) is a U.S.-listed healthcare company traded on the NYSE and one of the global leaders in animal health. Headquartered in Parsippany, New Jersey, United States, Zoetis traces its roots to Pfizer’s animal health business and became an independent public company following its IPO in 2013. Today, the company describes itself as the world’s leading animal health company and operates in more than 100 countries, with a commercial footprint spanning both the U.S. and international markets. ([zoetis.com](https://www.zoetis.com/our-company/our-story/about-us)) Zoetis discovers, develops, manufactures and commercializes a broad portfolio of vaccines, medicines, biopharmaceuticals, diagnostics and digital solutions for companion animals and livestock. Its business model is built around what it calls the “continuum of care,” covering prevention, detection and treatment. From an equity analysis perspective, the company stands out for its recurring revenue profile, premium brands, and science-led innovation across parasiticides, dermatology, pain management and livestock health. Key products and franchises include Simparica Trio, Apoquel, Librela, Cytopoint, and multiple cattle, swine and poultry offerings. ([zoetis.com](https://www.zoetis.com/our-company/our-story/about-us)) Competitive positioning is supported by Zoetis’ scale, global distribution, deep customer relationships and strong R&D engine. Management emphasizes an integrated strategy combining innovation, manufacturing excellence and commercial execution. In 2024, Zoetis reported 11% operational revenue growth and said it expanded its product portfolio through more than 100 geographic expansions and nearly 20 product enhancements. It also completed the divestiture of its medicated feed additive portfolio, certain water-soluble products and related assets on October 31, 2024, sharpening its focus on higher-priority segments. ([zoetis.com](https://www.zoetis.com/_assets/pdf/corporate/zoetis-2024-annual-report.pdf)) Recent corporate developments reinforce the company’s growth narrative. Throughout 2025, Zoetis announced several regulatory and product milestones, including approvals and label updates tied to major brands such as Simparica Trio, Librela and Lenivia. In its February 2026 full-year update, the company reported 2025 revenue of $9.5 billion and raised its 2026 outlook, signaling continued momentum in a structurally attractive animal-health market. For investors, Zoetis remains a quality defensive healthcare name with global reach, a strong innovation pipeline and a diversified mix between companion animal and livestock businesses. ([news.zoetis.com](https://news.zoetis.com/press-releases/press-release-details/2026/Zoetis-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx))